|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAEA |
Gene summary for MAEA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAEA | Gene ID | 10296 |
| Gene name | macrophage erythroblast attacher, E3 ubiquitin ligase | |
| Gene Alias | EMLP | |
| Cytomap | 4p16.3 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | B3KRN7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10296 | MAEA | LZE2T | Human | Esophagus | ESCC | 4.97e-02 | 1.80e-01 | 0.082 |
| 10296 | MAEA | LZE4T | Human | Esophagus | ESCC | 2.12e-02 | -3.95e-02 | 0.0811 |
| 10296 | MAEA | LZE7T | Human | Esophagus | ESCC | 3.80e-02 | 3.48e-01 | 0.0667 |
| 10296 | MAEA | LZE8T | Human | Esophagus | ESCC | 1.52e-05 | 3.43e-01 | 0.067 |
| 10296 | MAEA | LZE20T | Human | Esophagus | ESCC | 1.82e-09 | 2.71e-01 | 0.0662 |
| 10296 | MAEA | LZE22D1 | Human | Esophagus | HGIN | 4.85e-05 | 9.10e-02 | 0.0595 |
| 10296 | MAEA | LZE22T | Human | Esophagus | ESCC | 5.37e-03 | 2.07e-01 | 0.068 |
| 10296 | MAEA | LZE24T | Human | Esophagus | ESCC | 1.09e-13 | 1.24e-01 | 0.0596 |
| 10296 | MAEA | P1T-E | Human | Esophagus | ESCC | 9.56e-10 | 2.70e-01 | 0.0875 |
| 10296 | MAEA | P2T-E | Human | Esophagus | ESCC | 2.34e-37 | 6.43e-01 | 0.1177 |
| 10296 | MAEA | P4T-E | Human | Esophagus | ESCC | 9.78e-14 | 3.04e-01 | 0.1323 |
| 10296 | MAEA | P5T-E | Human | Esophagus | ESCC | 9.90e-11 | 1.24e-01 | 0.1327 |
| 10296 | MAEA | P8T-E | Human | Esophagus | ESCC | 4.67e-24 | 4.39e-01 | 0.0889 |
| 10296 | MAEA | P9T-E | Human | Esophagus | ESCC | 2.37e-17 | 1.86e-01 | 0.1131 |
| 10296 | MAEA | P10T-E | Human | Esophagus | ESCC | 3.19e-24 | 4.26e-01 | 0.116 |
| 10296 | MAEA | P11T-E | Human | Esophagus | ESCC | 7.86e-14 | 4.68e-01 | 0.1426 |
| 10296 | MAEA | P12T-E | Human | Esophagus | ESCC | 2.69e-19 | 3.65e-01 | 0.1122 |
| 10296 | MAEA | P15T-E | Human | Esophagus | ESCC | 1.82e-15 | 2.92e-01 | 0.1149 |
| 10296 | MAEA | P16T-E | Human | Esophagus | ESCC | 6.04e-27 | 6.09e-01 | 0.1153 |
| 10296 | MAEA | P17T-E | Human | Esophagus | ESCC | 2.24e-12 | 6.74e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
| GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
| GO:000734610 | Esophagus | HGIN | regulation of mitotic cell cycle | 98/2587 | 457/18723 | 4.39e-06 | 1.42e-04 | 98 |
| GO:003009927 | Esophagus | HGIN | myeloid cell differentiation | 83/2587 | 381/18723 | 1.26e-05 | 3.52e-04 | 83 |
| GO:003410127 | Esophagus | HGIN | erythrocyte homeostasis | 34/2587 | 129/18723 | 1.16e-04 | 2.43e-03 | 34 |
| GO:003021826 | Esophagus | HGIN | erythrocyte differentiation | 31/2587 | 120/18723 | 3.35e-04 | 5.50e-03 | 31 |
| GO:000226227 | Esophagus | HGIN | myeloid cell homeostasis | 37/2587 | 157/18723 | 6.63e-04 | 9.04e-03 | 37 |
| GO:004887227 | Esophagus | HGIN | homeostasis of number of cells | 54/2587 | 272/18723 | 3.50e-03 | 3.23e-02 | 54 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:0002262111 | Esophagus | ESCC | myeloid cell homeostasis | 104/8552 | 157/18723 | 1.49e-07 | 2.36e-06 | 104 |
| GO:0034101111 | Esophagus | ESCC | erythrocyte homeostasis | 88/8552 | 129/18723 | 1.81e-07 | 2.84e-06 | 88 |
| GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
| GO:0030218111 | Esophagus | ESCC | erythrocyte differentiation | 80/8552 | 120/18723 | 2.69e-06 | 3.08e-05 | 80 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
| GO:003410122 | Liver | HCC | erythrocyte homeostasis | 79/7958 | 129/18723 | 1.32e-05 | 1.47e-04 | 79 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAEA | SNV | Missense_Mutation | novel | c.287N>G | p.Ala96Gly | p.A96G | Q7L5Y9 | protein_coding | tolerated(0.31) | benign(0.009) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
| MAEA | insertion | In_Frame_Ins | novel | c.272_273insAGCACAGGCCTGGAA | p.Ala91_Glu92insAlaGlnAlaTrpAsn | p.A91_E92insAQAWN | Q7L5Y9 | protein_coding | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MAEA | insertion | Nonsense_Mutation | novel | c.274_275insTTTCTATCTAGCCCGATTCATTTTT | p.Glu92ValfsTer4 | p.E92Vfs*4 | Q7L5Y9 | protein_coding | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MAEA | insertion | Frame_Shift_Ins | novel | c.285_286insACTTCCAAAGG | p.Ala96ThrfsTer37 | p.A96Tfs*37 | Q7L5Y9 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| MAEA | SNV | Missense_Mutation | novel | c.973G>A | p.Ala325Thr | p.A325T | Q7L5Y9 | protein_coding | deleterious(0.02) | benign(0.366) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAEA | SNV | Missense_Mutation | c.520N>A | p.Glu174Lys | p.E174K | Q7L5Y9 | protein_coding | tolerated(0.13) | possibly_damaging(0.688) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MAEA | SNV | Missense_Mutation | rs765652453 | c.371N>A | p.Arg124His | p.R124H | Q7L5Y9 | protein_coding | deleterious(0.03) | probably_damaging(0.972) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| MAEA | SNV | Missense_Mutation | rs765652453 | c.371N>A | p.Arg124His | p.R124H | Q7L5Y9 | protein_coding | deleterious(0.03) | probably_damaging(0.972) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| MAEA | SNV | Missense_Mutation | c.135N>G | p.Ser45Arg | p.S45R | Q7L5Y9 | protein_coding | tolerated(0.11) | possibly_damaging(0.449) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| MAEA | SNV | Missense_Mutation | c.746N>T | p.Thr249Met | p.T249M | Q7L5Y9 | protein_coding | deleterious(0.01) | possibly_damaging(0.838) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |